세포 치료 및 유전자 치료 시장 규모, 점유율, 성장 분석 : 치료법별, 모달리티별, 적응증별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Cell & Gene Therapy Market size was valued at USD 29.44 Billion in 2024 and is poised to grow from USD 34.88 Billion in 2025 to USD 135.62 Billion by 2033, growing at a CAGR of 18.5% during the forecast period (2026-2033).

The growing prevalence of chronic conditions, including cancer, cardiovascular diseases, and rare genetic disorders, significantly propels the cell and gene therapy market. Existing treatments often do not provide long-term solutions, leading healthcare providers and pharmaceutical companies to seek groundbreaking therapies that offer targeted, personalized approaches. As more patients are diagnosed, driven by improved screening and an aging demographic, the demand for advanced therapies intensifies, fostering increased investment, clinical trials, and commercialization globally. Technological innovations, particularly in gene editing techniques like CRISPR-Cas9, are pivotal in this market, allowing for precise DNA modifications that enhance patient safety and regulatory viability. This progress not only streamlines research and development timelines and costs but also amplifies the potential for successful therapies, driving expansion in this dynamic sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell & Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell & Gene Therapy Market Segments Analysis

The global cell and gene therapy market is segmented based on therapy type, therapeutic class, end-users, and region. In terms of therapy type, the market is bifurcated into cell therapy and gene therapy. Based on therapeutic class, the market is segmented into cardiovascular disease, cancer, genetic disorder, rare diseases, oncology, hematology, ophthalmology, infectious disease, neurological disorders, and others. Based on end-users, the market is trifurcated into hospitals, cancer care centers, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Central & South America and the Middle East & Africa.

Driver of the Global Cell & Gene Therapy Market

The increasing prevalence of genetic disorders and rare diseases significantly propels the advancement of the cell and gene therapy market. These innovative therapies present the opportunity for cures for conditions that were once considered untreatable. As more patients seek solutions and the accuracy of diagnostic tools enhances, there is a notable surge in demand for specialized, effective treatments. This growing interest in targeted therapies further drives the expansion and evolution of the global cell and gene therapy sector, highlighting the urgent need for innovative approaches in addressing complex health challenges.

Restraints in the Global Cell & Gene Therapy Market

The Global Cell & Gene Therapy market faces significant restraints due to the demanding nature of developing these therapies, which requires comprehensive preclinical research, intricate clinical trials, and strict regulatory approvals. The extended timelines associated with these processes hinder timely market entry and elevate research and development costs. This challenge is particularly pronounced for smaller companies, as they often find it difficult to navigate the prolonged investment cycles, ultimately impacting their ability to innovate and accelerate the introduction of new therapies on a global scale. As a result, the market experiences limitations in maximizing its potential and advancing treatment options.

Market Trends of the Global Cell & Gene Therapy Market

The global cell and gene therapy market is witnessing a transformative shift towards personalized medicine, which tailors treatments to individual genetic profiles. This innovative approach not only enhances the effectiveness of therapies but also minimizes adverse effects, making it particularly beneficial for patients with rare and complex conditions. The focus on personalized solutions is fostering substantial advancements in research and development, encouraging pharmaceutical companies to pioneer targeted therapies that cater to diverse patient needs. As a result, this trend is propelling market growth, emphasizing the importance of patient-centric strategies in the evolving landscape of healthcare solutions.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Cell and Gene Therapy Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Cell Therapy
• Gene Therapy

Global Cell and Gene Therapy Market Size by Modality & CAGR (2026-2033)

• Market Overview
• In Vivo
• Ex Vivo

Global Cell and Gene Therapy Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Musculoskeletal Disorders
• Ophthalmic Disorders
• Metabolic & Genetic Disorders
• Infectious Diseases
• Others

Global Cell and Gene Therapy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Academic & Research Institutes
• Biopharmaceutical & Biotechnology Companies
• Cell Therapy Centers

Global Cell and Gene Therapy Market Size & CAGR (2026-2033)

• North America (Therapy Type, Modality, Indication, End User)
  • US
  • Canada
• Europe (Therapy Type, Modality, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Modality, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Modality, Indication, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Modality, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bluebird bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellectis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UniQure
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regenxbio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spark Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fosun Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aevitas Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Treadwell Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allogene Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations